Skip to main content
. 2015 Jan 12;11(4):259–280. doi: 10.5114/pwki.2015.55596

Table VI.

Studies investigating the genotype and its association with bleeding or ischemic events

Study author/acronym Polymorphism N Population Follow-up Outcome OR/HR Prevalence (%): carriers Prevalence (%): homozygote Prevalence (%): heterozygote
Thrombosis: CYP2C19*2, 3, *4, *5
AFIJI [152] 2C19*2 259 MI (< 45 years of age) 6 months MACE 3.69 28 0 25
AFIJI [150] 2C19*2 371 MI (< 45 years of age) 6 years MACE 2.26 31 4 26
TRITON TIMI-38 [153] 2C19*2 1477 PCI+ACS 15 months MACE 1.53 34
Oh et al. [202] 2C19*2 2146 PCI+DES 1 year MACE 2.62 47
Shuldiner et al. [154] 2C19*2 227 Elective PCI 1 year MACE 2.42 33 2 31
RECLOSE [151] 2C19*2 772 PCI 6 months ST 3.43 32 3 29
Harmsze et al. [149] 2C19*2 176/420 PCI (ST case/control) 1 year ST 1.7 40 5 35
Sibbing et al. [203] 2C19*2 2485 PCI 30 days ST 3.81 27 2 25
Sibbing et al. [165] 2C19*2 127/1439 PCI (ST case/control) 30 days ST 2.27 25 2 23
ONASSIST [87] 2C19*2 123/246 PCI (ST case/control) ST 1.99 49 16 33
Harmsze et al. [96] 2C19*2 725 Elective PCI 1 year MACE NS 31 3 28
Campo et al. [120] 2C19*2 300 PCI 1 year MACE NS 27 2 25
CHARISMA [156] 2C19*2 4819 CAD or at high risk 2 years MACE NS 15
Tiroch et al. [204] 2C19*2 928 MI 1 year MACE NS 27 2 25
Sawada et al. [205] 2C19*2 100 PCI+DES 8 months MACE NS 42
Tello-Montoliu et al. [206] 2C19*2 428 NSTE-ACS 6 months MACE NS 28 3 25
Malek et al. [207] 2C19*2 261 ACS 1 year Death NS 21 2 19
PEGASUS-PCI [63] 2C19*2 416 PCI 1 year ST NS 20 2 18
Jeong et al. [159] 2C19*2 and *3 266 MI 1 year MACE 2.81 45 8 37
FAST-MI [158] 2C19*2,3,*4,*5 2208 PCI+MI 1 year MACE 1.98 28 2 26
Yamamoto et al. [208] 2C19*2 or *3 123 CAD 12 months MACE 44 11 33
CURE and ACTIVE [209] 2C19*2 or *3 5059 ACS or AF 1 year MACE NS 20 2 18
PLATO [210] 2C19*2-*8 10285 ACS 30 days MACE 1.37 20 2 18
Harmsze et al. [149] 2C9*3 176/420 PCI (ST case/control) 1 year ST 2.4 16 1 15
ONASSIST [87] 2C9*3 123/246 PCI (ST case/control) ST NS 17 0 17
Harmsze et al. [149] CYP3A4*1B 176/420 PCI (ST case/control) 1 year ST NS 9 2 7
Suh et al. [211] CYP3A5*3 348 PCI 6 months MACE 4.89 45
Harmsze et al. [149] CYP3A5*3 176/420 PCI (ST case/control) ST NS 13 0 13
FAST-MI [158] CYP3A5*3 2208 PCI+MI 1 year MACE NS 17 1 16
Campo et al. [120] CYP3A5*3 300 PCI 1 year MACE NS 13 1 12
ONASSIST [87] CYP3A5*3 123/246 PCI (ST case/control) ST NS 20 4 16
Bleeding: CYP2C19*17
Sibbing et al. [160] 2C19*17 1524 PCI 30 days TIMI major bleeding 1.8 41 5 36
Campo et al. [120] 2C19*17 300 PCI 1 year TIMI major bleeding 2.3 34 6 28
Harmsze et al. [212] 2C19*17 820 Elective PCI 1 year TIMI major bleeding 2.7
Jeong et al. [159] 2C19*17 266 MI 1 year TIMI major bleeding NS 1 0 1
PLATO [210] 2C19*17 10285 ACS 1 year Major bleeding 1.25 32 5 27
CURE and ACTIVE [209] 2C19*17 5059 ACS or AF 1 year Major bleeding NS 34
CHARISMA [156] 2C19*17 4819 CAD or at high risk 2 years GUSTO severe bleeding NS 22
PEGASUS-PCI [63] 2C19*17 416 PCI 1 year TIMI major bleeding NS 34 4 30
Thrombosis: PON1
Bouman et al. [164] PON1 1982 ACS 1 year ST 12.80 54 13 41
EXCELSIOR [166] PON1 760 Elective PCI 1 year MACE NS 50 10 40
Sibbing et al. [165] PON1 127/1439 PCI (ST case/control) 30 days ST NS 47 8 39
Campo et al. [163] PON1 300 PCI 1 month MACE NS 76 27 49
Simon et al. [167] PON1 2210 MI 1 year MACE NS
AFIJI [150] PON1 371 MI (< 45 years of age) 6 years MACE NS 55 15 40
Thrombosis: ACBC1
TRITON TIMI 38 [213] ABCB1 2932 ACS+PCI 15 months MACE 1.72 73 23 50
FAST-MI [158] ABCB1 2208 PCI+MI 1 year MACE 1.72 74 26 48
ONASSIST [87] ABCB1 123/246 PCI (ST case/control) ST 2.16 76 32 44
Jaitner et al. [162] ABCB1 66/1408 PCI (ST case/control) ST NS 78 29 49
Campo et al. [163] ABCB1 300 PCI 1 year MACE NS 77 25 52
PLATO [210] ABCB1 10285 ACS 1 year MACE NS 76 27 49
Harmsze et al. [149] ABCB1 176/420 PCI (ST case/control) 1 year ST NS 68 14 54
Jeong et al. [159] ABCB1 266 MI 1 year MACE NS 54 13 41
Spiewak et al. [214] ABCB1 98 ACS+PCI 1.7 years MACE NS 72 21 51
Tiroch et al. [204] ABCB1 928 MI 12 months MACE NS 82 29 49
Thrombosis: ITGB3, P2Y12, IRS-1
ONASSIST [87] ITGB3 123/246 PCI (ST case/control) ST 0.52 16 0 16
FAST-MI [158] ITGB3 2208 PCI+MI 1 year MACE NS 29 2 27
Ziegler et al. [215] P2Y12 137 PAD 2 years Neurological event 4.02 31 4 27
FAST-MI [158] P2Y12 2208 PCI+MI 1 year MACE NS 25 3 25
ONASSIST [87] P2Y12 123/246 PCI (ST case/control) ST NS 32 5 27
Angiolillo et al. [169] IRS-1 187 DM+CAD 2 years MACE 2.88 31 NN NN

AF – atrial fibrillation, PCI – percutaneous coronary intervention, NSTE-ACS – non ST-elevation acute coronary syndrome, MACE – major adverse cardiac events, MI – myocardial infarction, ST – stent thrombosis, PAD – periphery artery disease, DES – drug eluting stent, CAD – coronary artery disease, TIMI – thrombolysis in myocardial infarction, DM – diabetes mellitus, NS – not significant.